Literature DB >> 28573433

Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors".

Stefan Michiels1,2,3, Everardo D Saad4, Marc Buyse5,6.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28573433     DOI： 10.1007/s40265-017-0761-x

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  5 in total

1.  Assessing survival benefit when treatment delays disease progression.

Authors:  David A Schoenfeld; Dianne M Finkelstein
Journal:  Clin Trials       Date:  2016-02-22       Impact factor: 2.486

2.  Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.

Authors:  Audrey Mauguen; Stefan Michiels; Virginie Rondeau
Journal:  J Biopharm Stat       Date:  2017-03-20       Impact factor: 1.051

3.  Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.

Authors:  David A Schoenfeld
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

4.  Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.

Authors:  Stefan Michiels; Everardo D Saad; Marc Buyse
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.

Authors:  Xabier García-Albéniz; Joan Maurel; Miguel A Hernán
Journal:  Int J Cancer       Date:  2014-11-03       Impact factor: 7.396
  5 in total
  1 in total

1.  Physicians' Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer.

Authors:  Yi Zhang; Miao Liu; Houpu Yang; Shu Wang
Journal:  Breast Care (Basel)       Date:  2021-08-20       Impact factor: 2.268
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.